Aratana Therapeutics — Merger or Acquisition (January 2014)
19 slides from Aratana Therapeutics's merger presentation, Jan 7, 2014
Slide 1: January 6,
January 6, 2014 Exhibit 99.2
Slide 2: Special Note Regarding Forward-Looking Statements
2 Special Note Regarding Forward-Looking Statements Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact s
Slide 3: Investment Highlights
3 Investment Highlights Large, growing market De-risked drug development Private-pay Portfolio approach Scalable and capital-efficient Pure-play, first mover
Slide 4: Acquisition of Okapi Sciences NV
4 Acquisition of Okapi Sciences NV Strategic Rationale Provides a European base of operations and footprint Enhances product portfolio with six additional product candidates bringing the PETX pipeline to > 20 products Additional de novo product generation capability Antivirals are an underserved mar
Slide 5: Okapi Sciences NV
5 Okapi Sciences NV Leuven, Belgium
Slide 6: Okapi Key Personnel
6 Okapi Key Personnel Dr. Erwin Blomsma — PhD ‘95 / Postdoc at KU Leuven — Janssen Pharmaceutical — Avantium / Crystallics Professor Dr. Johan Neyts — PhD ’93 / PostDoc University of North Carolina — Source of know-how and IP Dr. Stefaan Wera PhD ‘92 / Postdoc at Academic Institute, Basel Belgian bi
Slide 7: Okapi Key Relationships
7 Okapi Key Relationships - Discovery research - Development research - Project management - Regulatory - Business development - Operational support - Management - IP, rights - Know-how - PoC work - Medchem Academia / Industry - Joint R&D - Distribution - M&S - PhV - R&D support L D R Partners - Inv
Slide 8: Lack of Antivirals for Pets
8 Feline Herpesvirus Calicivirus Parvo Virus FIV 80% of pets get viral infections Only symptoms can be treated, not the infection Under-recognized, under- diagnosed Lack of Antivirals for Pets
Slide 9: Okapi Pipeline
9 Feline immunodeficiency Feline herpes Canine drug – Lymphoma Canine drug – Parvovirus Feline drug – Calicivirus De Novo Okapi Pipeline *Referring to expected first launch in US or Europe Pre-Clinical Clinical Approval Launch* 2015 2017 2017+ 2018+ 2018+ 2019+
Slide 10: AT-006 Feline Herpes
10 Calici Herpes FIV FELV FIP Parvo Feline Herpes is a common virus in cats – 95% of cats exposed – 3% with symptoms in US and EU – Ocular symptoms most common Vaccinations are only option – Kittens vaccinated at 6 weeks Similar to humans, virus not cured AT-006 Feline Herpes I n c i d e n c e
Slide 11: AT-007 Feline immunodeficiency virus
11 Calici Herpes FIV FELV FIP Parvo FIV is a serious viral disease in cats – 2% incidence in the US – >10% incidence in parts of Europe and Asia Vaccinations are only option (US only) – Kittens vaccinated at 6 weeks – Not fully protective Cats can have shorter lives after infection and illness AT-00
Slide 12: Other Assets
12 Other Assets Production animal products – Molecules may work in livestock and could become crucial in containing viral outbreaks – Swine Flu, Foot & Mouth Disease, etc. – Funded largely with subsidies and grants – To be divested or spun-out after value inflection – Production animal companies hav
Slide 13: Key Attributes Early De-Risking
13 Key Attributes Early De-Risking Portfolio Construction Toxicology data are available Effectiveness data are available Manufacturing is scaled-up Unmet medical need High incidence or prevalence Known mechanism of action Nuance in science “ Early de - risking ” Leveraging the investment in human th
Slide 14: De-Risked Product Development
14 De-Risking YR1 YR2 YR3 YR4 YR5 YR6 YR7 YR8 YR9 YR10 YR11 YR12 YR13 De-Risked Product Development Proof of Concept in Lab Animals Animal Toxicology SAR Chemistry, Selection of Lead Animal pK In vitro Chemistry Optimization IND Filing Human Clinical Studies Phase I Phase II Final Formulation Phase
Slide 15: Aratana's Pipeline
15 Lymphoma Diagnostic AT-013 Cat Lymphoma AT-010 Dog Atopic Dermatitis AT-009 Mast Cell – Dog Option 1 Alpha AT-002 Dog Appetite Stimulant Option 2 Beta AT-003 Dog Post-operative Pain AT-004 Dog B-Cell Lymphoma Option 3 Gamma AT-003 Cat Post-operative pain AT-005 Dog T-Cell Lymphoma AT-001 Cat Oste
Slide 16: Deal Structure
16 Deal Structure Approximately €33.3M total consideration Stock Purchase €10.3M cash paid at closing €11M promissory note Due December 31, 2014, subject to mandatory prepayment upon an equity financing 7% interest €12M post-closing consideration Due April 7, 2014, subject to mandatory prepayment in
Slide 17: Top Institutional Investors
17 Top Institutional Investors Our Financial Profile Partnering opportunities globally Out-licensing of non-core products Advancing product portfolio Begin to build commercial capabilities Fund operations through 2014 Wellington Management Adage Capital Partners Special Situations Funds JPMorgan Cha
Slide 18: Big Animal Health Biotech Landscape
18 Big Animal Health Biotech Landscape Canfel Therapeutics
Slide 19: Investment Highlights
19 Investment Highlights Large, growing market De-risked drug development Private-pay Portfolio approach Scalable and capital-efficient Pure-play, first mover
Aratana Therapeutics — Merger or Acquisition (January 2014) on 6ix